Table 2 Randomly selected cohort: HPV prevalence by cytology result of index smear

From: Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort

  Normal smeara Any abnormality Total
   Any HPV High riskb HPV   Any HPV High riskb HPV   Any HPV High-riskb HPV HPV 16
Age Total n % n % Total n % n % Total n % n % n %
15–19 319 64 20.1 55 17.2 19 17 89.5 14 73.7 338 81 24.0 69 20.4 33 9.8
20–24 466 89 19.1 75 16.1 41 24 58.5 17 41.5 507 113 22.3 92 18.2 43 8.5
25–29 586 81 13.8 61 10.4 61 38 62.3 32 52.5 647 119 18.4 93 14.4 40 6.2
30–34 1191 96 8.1 53 4.5 72 35 48.6 33 45.8 1263 131 10.4 86 6.8 42 3.3
35–39 914 36 3.9 23 2.5 49 26 53.1 24 49.0 963 62 6.4 47 4.9 22 2.3
40–44 926 26 2.8 15 1.6 46 17 37.0 13 28.3 972 43 4.4 28 2.9 13 1.4
45–49 508 18 3.5 11 2.2 19 4 21.1 4 21.1 527 22 4.2 15 2.9 6 1.1
50–54 1104 32 2.9 18 1.6 27 12 44.4 11 40.7 1131 44 3.9 29 2.6 17 1.5
55–69 114 2 1.8 1 0.9 114 2 1.8 1 0.9
Total 6128 444 7.3 312 5.1 334 173 51.8 148 44.3 6462 617 9.6 460 7.1 216 3.3
  1. aIncludes 175 with infection.
  2. bHigh-risk HPV types: 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68.
  3. Prevalence of each HR-HPV type among the 460 HR-HPV infected women in the random cohort overall, and without another HR-HPV type: HPV16: 47.0%, 39.8%. HPV18: 16.7%, 12.0%. HPV26: 0.0%, 0.0%. HPV31: 13.0%, 8.7%. HPV33: 8.5%, 6.5%. HPV35: 1.1%, 0.7%. HPV39: 2.4%, 0.9%. HPV45: 4.8%, 3.5%. HPV51: 0.7%, 0.2%. HPV52: 3.9%, 2.0%. HPV53: 7.4%, 3.3%. HPV56: 5.0%, 2.0%. HPV58: 6.3%, 3.7%. HPV59: 1.7%, 1.3%. HPV66: 0.0%, 0.0%. HPV68: 0.0%, 0.0%.